2016 Advances for Practitioners
Recorded On: 11/14/2016
- Registration Closed
This program will provide trainees and practitioners with a careful review of highly impactful and clinically relevant papers in the management of alcoholic liver disease and NAFLD. Learn the caveats associated with the design, application and final message of key clinical studies, and identify the areas of that need further study. A special focus on emerging trends in the field and how these may impact the clinical management of alcoholic liver disease and BAFLD in coming years will be discussed.
Philippe Mathurin
Brent A. Tetri
Brent Neuschwander-Tetri, MD is a Professor of Internal Medicine and Associate Chair for Clinical Research at Saint Louis University. Dr. Neuschwander-Tetri completed his undergraduate studies at the University of Oregon received his MD from Yale University. He completed his internship and residency in internal medicine at the University of Wisconsin Madison and his fellowship in gastroenterology and hepatology at the University of California San Francisco, working in the UCSF Liver Center Laboratory. In 1991, Dr. Neuschwander-Tetri joined Dr. Bruce Bacon and the faculty at Saint Louis University in the Division of Gastroenterology and Hepatology. He is actively involved in clinical care of patients with liver disease, laboratory research and clinical trials. His laboratory work demonstrated severe NASH in mice fed trans-fats and he continues to explore mechanisms of lipotoxic liver injury and fibrogenesis. He is a member of the NIH-supported NASH Clinical Research Network, the group that conducted the PIVENS and FLINT treatment trials for NASH, and is a steering committee member of the international TARGET NASH consortium. He speaks nationally and internationally to academic and industry groups on the molecular pathogenesis of NASH and targets of therapy that address substrate-overload lipotoxic liver injury.
